drug · small molecule
adagrasib
Marketedupdated 5mo agoby Bristol-Myers Squibb Co🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 1 investigational indication.
indications
investigational
NSCLCBreast CancerColorectal Cancer
targets
GTPase KRas
all catalysts(0)
nothing on the calendar yet
Trials studying adagrasib
- phase3A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- phase2A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
- phase3Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- phase3A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
- phase1A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
- phase1KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- phase2Genetic Testing in Guiding Treatment for Patients With Brain Metastases
- phase1Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 12, 2027
~1.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Aug 21, 2043formulationUS 12383503
- Sep 10, 2041compositionUS 12281113
- Feb 5, 2041method-of-use (U-3953)US 12336995
- May 17, 2037compositionUS 10689377
FDA exclusivities (2)
- Dec 12, 2029ODE-352Orphan Drug (7y)3.2y
- Dec 12, 2027NCENew Chemical Entity (5y)1.2y
News(6)
- Krazati withdrawal completed; Wegovy trial meets endpoint for kids ages 6 to 12Plus news about Structure Therapeutics, Cloverleaf Bio and Windward Bio. FDA finalizes Krazati withdrawal: Regulators officially finalized the drug’s withdrawal in second-line colorectal cancer las…endpoints · 22d ago
- GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer assetGSK is handing over $110 million upfront to Hutchmed in a deal worth up to $1.295 billion to get its hands on a first-in-class oncology candidate.fiercebiotech · 27d ago
- Bristol Myers details Krazati confirmatory study failure in colorectal cancerWhile Americans geared up for the July 4 holiday, Bristol Myers Squibb laid out how a confirmatory trial for its drug Krazati failed in colorectal cancer. Patients taking Krazati plus another drug,…endpoints · 2mo ago
- Roche KRAS drug succeeds in head-to-head lung cancer studyThe Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.biopharma_dive · 3mo ago
- ‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancerHighly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.biopharma_dive · 4mo ago
- Krazati fails confirmatory trial in colorectal cancer, putting approval at riskBristol Myers Squibb’s cancer drug Krazati has failed its confirmatory study in second-line colorectal cancer, a company spokesperson confirmed to Endpoints News. Krazati had received accelerated a…endpoints · 5mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that